PRIVATE ENVIRONMENTAL GOVERNANCE TO ADDRESS MANUFACTURING RELEASES OF ANTIBIOTICS.

India; China

Demand for generic pharmaceuticals has resulted in China and India becoming the largest producers of these products in the world. Pollution from pharmaceutical manufacturing in both of these countries is a recognized environmental and public health problem, and the release of residual antibiotics is a contributor to antimicrobial resistance, which is projected to result in 10 million deaths per year by 2050 unless significant action is taken. This Article argues that implementation of voluntary sustainability standards is needed to address pharmaceutical manufacturing wastewater pollution, that this approach would drive market demand for pharmaceuticals produced in this way, and that this market response should also drive other manufacturers to improve their operations. [ABSTRACT FROM AUTHOR]

Copyright of Environmental Law Reporter: News & Analysis is the property of Environmental Law Institute and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)